ATE169019T1 - Xanthinderivate als adenosin-a1 rezeptor antagonisten - Google Patents
Xanthinderivate als adenosin-a1 rezeptor antagonistenInfo
- Publication number
- ATE169019T1 ATE169019T1 AT94910661T AT94910661T ATE169019T1 AT E169019 T1 ATE169019 T1 AT E169019T1 AT 94910661 T AT94910661 T AT 94910661T AT 94910661 T AT94910661 T AT 94910661T AT E169019 T1 ATE169019 T1 AT E169019T1
- Authority
- AT
- Austria
- Prior art keywords
- adenosine
- pct
- receptor antagonists
- xanthine derivatives
- sec
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
- C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
- C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US2350193A | 1993-02-26 | 1993-02-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE169019T1 true ATE169019T1 (de) | 1998-08-15 |
Family
ID=21815459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT94910661T ATE169019T1 (de) | 1993-02-26 | 1994-01-27 | Xanthinderivate als adenosin-a1 rezeptor antagonisten |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US5840729A (de) |
| EP (1) | EP0686155B1 (de) |
| JP (1) | JPH08512281A (de) |
| KR (1) | KR100315898B1 (de) |
| CN (1) | CN1041418C (de) |
| AT (1) | ATE169019T1 (de) |
| AU (1) | AU680241B2 (de) |
| CA (1) | CA2155130C (de) |
| DE (1) | DE69412073T2 (de) |
| DK (1) | DK0686155T3 (de) |
| ES (1) | ES2120025T3 (de) |
| HU (1) | HUT72677A (de) |
| IL (1) | IL108750A (de) |
| MX (1) | MX9401406A (de) |
| NO (1) | NO311920B1 (de) |
| NZ (1) | NZ262984A (de) |
| TW (1) | TW261532B (de) |
| WO (1) | WO1994019349A1 (de) |
| ZA (1) | ZA941176B (de) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998041237A1 (fr) * | 1997-03-18 | 1998-09-24 | Fujisawa Pharmaceutical Co., Ltd. | Medicaments pour la prevention et la therapie de l'hyperphosphatemie |
| IL139787A0 (en) | 1998-06-02 | 2002-02-10 | Osi Pharm Inc | PYRROLO [2, 3d] PYRIMIDINE COMPOSITIONS AND THEIR USE |
| US6680322B2 (en) | 1999-12-02 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US6680324B2 (en) | 2000-12-01 | 2004-01-20 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A1 receptors and uses thereof |
| US20020115635A1 (en) * | 2001-02-21 | 2002-08-22 | Pnina Fishman | Modulation of GSK-3beta activity and its different uses |
| DK1450811T3 (da) | 2001-11-30 | 2010-02-15 | Osi Pharm Inc | Forbindelser specifikke af adenosin A1- og A3-receptorer og anvendelser heraf |
| US6916804B2 (en) | 2001-12-20 | 2005-07-12 | Osi Pharmaceuticals, Inc. | Pyrimidine A2b selective antagonist compounds, their synthesis and use |
| WO2003097582A2 (en) * | 2002-05-15 | 2003-11-27 | Genzyme Corporation | Synthesis of benzonitriles and benzimidates |
| WO2004086047A2 (en) * | 2003-03-28 | 2004-10-07 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor adenosine a1 (adora1) |
| AU2004296137A1 (en) * | 2003-12-09 | 2005-06-23 | Kyowa Hakko Kirin Co., Ltd. | Preventive and/or therapeutic agent for higher brain dysfunction |
| US7592461B2 (en) | 2005-12-21 | 2009-09-22 | Bristol-Myers Squibb Company | Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof |
| US7795427B2 (en) * | 2006-02-14 | 2010-09-14 | New York University | Methods for inhibiting osteoclast differentiation, formation, or function and for increasing bone mass |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE8817122U1 (de) * | 1988-12-22 | 1993-02-04 | Boehringer Ingelheim Kg, 55218 Ingelheim | Neue Xanthinderivate mit Adenosinantogenistischer Wirkung |
| US5047534A (en) * | 1990-03-26 | 1991-09-10 | Merrell Dow Pharmaceuticals Inc. | Selective adenosine receptor agents |
| DE4019892A1 (de) * | 1990-06-22 | 1992-01-02 | Boehringer Ingelheim Kg | Neue xanthinderivate |
| JPH0455150A (ja) * | 1990-06-22 | 1992-02-21 | Takata Kk | 助手席用エアバッグ装置 |
| US5087827A (en) * | 1991-02-11 | 1992-02-11 | Tektronix, Inc. | Variable voltage transition circuit |
| US5208240A (en) * | 1991-03-12 | 1993-05-04 | Merrell Dow Pharmaceuticals Inc. | 8-substituted purines as selective adenosine receptor agents |
| US5281607B1 (en) * | 1992-10-08 | 1998-05-19 | Univ New York | Method of using alpha 2-antagonists for the treatment of neurodegenerative diseases |
-
1994
- 1994-01-27 CN CN94191309A patent/CN1041418C/zh not_active Expired - Fee Related
- 1994-01-27 AU AU62968/94A patent/AU680241B2/en not_active Ceased
- 1994-01-27 JP JP6518986A patent/JPH08512281A/ja active Pending
- 1994-01-27 EP EP94910661A patent/EP0686155B1/de not_active Expired - Lifetime
- 1994-01-27 KR KR1019950703577A patent/KR100315898B1/ko not_active IP Right Cessation
- 1994-01-27 CA CA002155130A patent/CA2155130C/en not_active Expired - Fee Related
- 1994-01-27 HU HU9502495A patent/HUT72677A/hu unknown
- 1994-01-27 NZ NZ262984A patent/NZ262984A/en unknown
- 1994-01-27 WO PCT/US1994/001009 patent/WO1994019349A1/en active IP Right Grant
- 1994-01-27 AT AT94910661T patent/ATE169019T1/de not_active IP Right Cessation
- 1994-01-27 US US08/500,991 patent/US5840729A/en not_active Expired - Fee Related
- 1994-01-27 DK DK94910661T patent/DK0686155T3/da active
- 1994-01-27 ES ES94910661T patent/ES2120025T3/es not_active Expired - Lifetime
- 1994-01-27 DE DE69412073T patent/DE69412073T2/de not_active Expired - Fee Related
- 1994-02-21 ZA ZA941176A patent/ZA941176B/xx unknown
- 1994-02-22 TW TW083101485A patent/TW261532B/zh active
- 1994-02-23 IL IL10875094A patent/IL108750A/xx not_active IP Right Cessation
- 1994-02-24 MX MX9401406A patent/MX9401406A/es not_active IP Right Cessation
-
1995
- 1995-08-25 NO NO19953353A patent/NO311920B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| DE69412073T2 (de) | 1999-02-18 |
| HU9502495D0 (en) | 1995-10-30 |
| CA2155130C (en) | 1994-09-01 |
| IL108750A0 (en) | 1994-05-30 |
| WO1994019349A1 (en) | 1994-09-01 |
| NZ262984A (en) | 1997-05-26 |
| NO311920B1 (no) | 2002-02-18 |
| TW261532B (de) | 1995-11-01 |
| DE69412073D1 (de) | 1998-09-03 |
| CA2155130A1 (en) | 1994-09-01 |
| AU680241B2 (en) | 1997-07-24 |
| EP0686155A1 (de) | 1995-12-13 |
| CN1118599A (zh) | 1996-03-13 |
| JPH08512281A (ja) | 1996-12-24 |
| IL108750A (en) | 2000-09-28 |
| US5840729A (en) | 1998-11-24 |
| NO953353D0 (no) | 1995-08-25 |
| HUT72677A (en) | 1996-05-28 |
| KR100315898B1 (ko) | 2002-02-28 |
| NO953353L (no) | 1995-08-25 |
| CN1041418C (zh) | 1998-12-30 |
| ZA941176B (en) | 1994-09-20 |
| EP0686155B1 (de) | 1998-07-29 |
| DK0686155T3 (da) | 1999-02-01 |
| MX9401406A (es) | 1994-08-31 |
| ES2120025T3 (es) | 1998-10-16 |
| AU6296894A (en) | 1994-09-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE188379T1 (de) | Fibrinogenrezeptor-antagonisten | |
| DE69622031D1 (de) | INDOLDERIVATE ALS cGMP-PDE INHIBITOREN | |
| DE69318854D1 (de) | Spiroazacyclischderivate als substanz p antagonisten | |
| DE69616480D1 (de) | Piperidinderivate als neurokininantagonisten | |
| FI960727A (fi) | Neurokiniiniantagonisteina käyttökelpoiset heterosyklit | |
| ES2121193T3 (es) | Derivados de bencimidazoles. | |
| DE69611377D1 (de) | 1,2,4-triazolo[1,5-c]pyrimidin-heterocyclische analoge mit antagonistischer aktivität auf dem adenosine a2a rezeptor | |
| KR960701051A (ko) | 이미다조피리딘 및 이를 위장 질환의 치료에 사용하는 방법(imidazopyridines and their use in treating castrointestinal diseases) | |
| ATE169019T1 (de) | Xanthinderivate als adenosin-a1 rezeptor antagonisten | |
| TR199900501T2 (xx) | Benzamin t�revleri ve bunlar�n ila� olarak kullan�m�. | |
| DE69420394D1 (de) | Pyrrolopyridinderivate als dopaminrezeptor liganden | |
| DK0960111T3 (da) | Morphinderivat med analgesisk aktivitet | |
| IS1961B (is) | Notkun 1-(2-naft-2-ýletýl)-4(3-tríflúorómetýlfenýl)-1,2,3,6-tetrahýdrópýridíns til gerðar lyfja tilþess að meðhöndla hliðarstrengjahersli | |
| ATE189894T1 (de) | Naphthamidderivate von 3-beta-amino azabicyclooctan oder nonan als antipsychotische arzneimittel | |
| PL311296A1 (en) | Derivatives of benzo [f] quinoxalinodione, method of obtaining them and their application in therapeutic agents | |
| FR2695641B1 (fr) | (Amino-3 phényl)-1 éthanesulfonate d'hydroquinine optiquement actif, sa préparation et son utilisation. | |
| PT958290E (pt) | Derivados de 1,4-di-hidropiridina e seu uso em terapia | |
| ATE221068T1 (de) | Anellierte beta-carboline |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification | ||
| REN | Ceased due to non-payment of the annual fee |